Defects in DNA Repair Genes Confer Improved Long-term Survival after Cisplatin-based Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer (European Urology Oncology)

Mutations in ATM, RB1, and FANCC are associated with higher rates of pathologic complete response and significantly longer overall survival among patients with muscle-invasive bladder cancer who received neoadjuvant cisplatin-based chemotherapy before radical cystectomy.